GRA7与profilin蛋白联合疫苗抗慢性弓形虫感染的协同效应
本研究首次表征重组弓形虫profilin蛋白(rTgPF)作为佐剂及免疫原的潜力,在小鼠模型中单独或与GRA7抗原联合使用。rGRA7+rTgPF混合物比单一蛋白更有效激活小鼠骨髓来源树突状细胞,BALB/c小鼠接种后经淋巴细胞增殖、CD4+T细胞活化及IFN-γ产生诱导向Th1偏移的免疫,增强对慢性弓形虫感染的保护。profilin本身仅诱导细胞免疫,但与rGRA7联用时增强其免疫应答,提示rTgPF可作为蛋白疫苗的潜在佐剂。
要点
- rTgPF与rGRA7联用比单一蛋白更有效激活小鼠BMDCs,上调CD80/CD86并分泌IL-6、IL-10、IL-12。
- BALB/c小鼠接种rGRA7+rTgPF诱导向Th1偏移的免疫,增强对慢性弓形虫感染的保护。
- profilin本身仅诱导细胞免疫,联用时增强rGRA7免疫应答,提示其佐剂潜力。
核心结论
- rTgPF与rGRA7联合疫苗在小鼠模型中诱导向Th1偏移的免疫并增强对慢性弓形虫感染的保护,提示rTgPF可作为蛋白疫苗的潜在佐剂。
研究设计与样本
- 研究首次表征重组profilin蛋白(rTgPF)的佐剂和免疫原潜力,在鼠弓形虫模型中单独或与GRA7抗原联合使用。
- 体外评估rTgPF和rGRA7对小鼠骨髓来源树突状细胞(BMDCs)的激活,随后在BALB/c小鼠中开展疫苗接种实验。
主要发现
- rTgPF和rGRA7均能激活小鼠BMDCs,且两者联合比单一蛋白更有效,表现为CD80和CD86共刺激蛋白表达增加及IL-6、IL-10、IL-12细胞因子分泌。
- BALB/c小鼠接种rGRA7+rTgPF混合物后,通过诱导淋巴细胞增殖、CD4+T细胞活化和IFN-γ产生增加,诱导向Th1偏移的免疫。
- 该免疫应答增强了对慢性弓形虫感染的保护。
- profilin本身仅诱导细胞免疫,但与rGRA7联用时增强其免疫应答。
临床怎么用
- rTgPF可作为蛋白疫苗的潜在佐剂,与GRA7抗原联用以增强Th1型免疫应答。
- 该联合疫苗策略在小鼠模型中显示增强对慢性弓形虫感染的保护,需进一步转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Toxoplasmosis is a zoonotic disease with worldwide prevalence in humans and warm-blooded animal populations. In livestock Toxoplasma gondii is the causal agent of significant economic losses since it can cause abortions in goats and sheep. It is estimated that one third of the world population is infected. Although there are effective therapies for acute infection, these are sometimes poorly tolerated, teratogenic, and have a long administration time. Considering the deficiencies that exist related to the prevention and treatment of toxoplasmosis, the development of a safe and effective vaccine would be extremely valuable in fighting against this infection. In the present work, we characterize for the first time the adjuvant and immunogenic potential of a recombinant profilin protein (rTgPF), in a vaccine formulation alone or in combination with the well-known GRA7 antigen candidate in a murine toxoplasmosis model. Since TgPF acts as a ligand for TLR11 and 12 inducing innate immune responses that promote type 1 adaptive responses, we first study the capacity of the mix rGRA7 + rTgPF to initiate an immune response by evaluating dendritic cell activation. Both rTgPF and rGRA7 induces activation of mouse BMDCs more efficiently than the single proteins, evidenced by increased expression of CD80 and CD86 co-stimulatory proteins and secretion of IL-6, IL-10 and IL-12 cytokines after in vitro stimulation. The sum of the effects of rGRA7 and rTgPF on BMDCs maturation led us to assay them in a vaccination protocol. BALB/c mice vaccinated with this mix elicited a Th1-biased immunity via the induction of lymphocyte proliferation, activation of CD4+T cells and increased IFN-γ production that resulted in enhanced protection against chronic Toxoplama gondii infection. Profilin per se induce only cellular immunity but augments the effect of rGRA7 immune responses when used together, thus allowing us to postulate rTgPF as a potential adjuvant in a protein vaccine.
引用
- Arcon N, Picchio MS, Fenoy IM, et al. Synergistic effect of GRA7 and profilin proteins in vaccination against chronic Toxoplasma gondii infection. Vaccine. 2021. PMID: 33451777. doi:10.1016/j.vaccine.2020.12.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。